Vascular biology of magnesium and its transporters in hypertension.
Level 5 - mechanism / opinion, no new human data
Narrative mechanistic review with no original human empirical data.
PubMed 21199786 · doi:10.1684/mrh.2010.0222
What was done
This paper reviewed the vascular biology of magnesium (Mg2+) and its cellular transport pathways in relation to blood pressure regulation and cardiovascular disease. It specifically examined mechanisms of Mg2+ efflux (Na+-dependent and Na+-independent systems) and influx (including Mrs2p, SLC41A1, SLC41A2, ACDP2, MagT1, TRPM6, and TRPM7).
What was found
The abstract reports no quantitative values. It describes that magnesium acts as a calcium channel antagonist, stimulates nitric oxide and prostacyclin production, and alters vascular responsiveness to vasoconstrictors. Mechanistically, increased Mg2+ efflux via vascular Na+/Mg2+ exchangers and decreased influx via impaired TRPM6/7 expression or activity are highlighted as contributors to intracellular Mg2+ deficiency, altered vasomotor tone, and hypertension.
Why it matters
It provides a framework connecting molecular magnesium transporters in vascular and renal tissue to systemic blood pressure control and vascular tone abnormalities.
Limits
The abstract describes a narrative review of biological mechanisms rather than a systematic review, randomized trial, or clinical observational study. It reports no empirical sample sizes, confidence intervals, or quantitative effect estimates.
Cited by
- supports Magnesium lowers blood pressure by stimulating the production of prostacyclin and nitric oxide, which dilate blood vessels.